NEW YORK (GenomeWeb) – Natera said after the close of the market on Wednesday that its third quarter 2016 revenues climbed 20 percent year over year. 

For the three months ended Sept. 30, the molecular diagnostics firm brought in $53.9 million in revenues compared to $44.9 million in Q3 2015, and beating analysts' average estimate of $48.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sep
27

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs. 

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.